GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » NovMetaPharma Co Ltd (XKRX:229500) » Definitions » Other Gross PPE

NovMetaPharma Co (XKRX:229500) Other Gross PPE : ₩961.31 Mil (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is NovMetaPharma Co Other Gross PPE?

NovMetaPharma Co's Other Gross PPE for the quarter that ended in Dec. 2023 was ₩961.31 Mil.

NovMetaPharma Co's quarterly Other Gross PPE increased from Dec. 2021 (₩855.73 Mil) to Dec. 2022 (₩864.36 Mil) and increased from Dec. 2022 (₩864.36 Mil) to Dec. 2023 (₩961.31 Mil).

NovMetaPharma Co's annual Other Gross PPE increased from Dec. 2021 (₩855.73 Mil) to Dec. 2022 (₩864.36 Mil) and increased from Dec. 2022 (₩864.36 Mil) to Dec. 2023 (₩961.31 Mil).


NovMetaPharma Co Other Gross PPE Historical Data

The historical data trend for NovMetaPharma Co's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovMetaPharma Co Other Gross PPE Chart

NovMetaPharma Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Gross PPE
Get a 7-Day Free Trial Premium Member Only 564.56 810.88 855.73 864.36 961.31

NovMetaPharma Co Semi-Annual Data
Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Gross PPE Get a 7-Day Free Trial Premium Member Only 564.56 810.88 855.73 864.36 961.31

NovMetaPharma Co Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


NovMetaPharma Co Business Description

Traded in Other Exchanges
N/A
Address
727 13, Gangnam-gu, Seoul eonju layer, Seoul, KOR
NovMetaPharma Co Ltd researches and develops new medicines and health supplements for metabolic diseases. The company is developing a therapeutic agent that is in Phase 2a clinical trial for Type 2 diabetes and obesity. It also develops therapeutic agents for Alzheimer's disease, immune system diseases, osteoporosis, and non-alcoholic fatty liver diseases.

NovMetaPharma Co Headlines

No Headlines